Our Approach

With our clinical science-driven approach, we are pioneering the development of ITK inhibition and other precisely-targeted medicines for cancer, immune disorders and infectious diseases.

Our mission is to develop improved medicines to treat patients with difficult-to-treat diseases by furthering the science behind drug development. We are focused on developing ITK inhibition as a new approach to immunotherapy with a differentiated mechanism of action that targets T cells, which are critical to the immune response to both hematologic and solid cancers, and immune diseases.

In addition to ITK inhibitions, we have developed a pipeline of investigational agents – both small molecules and antibodies – that are designed to precisely modulate molecular targets that are well-defined and measurable. This allows us to identify biomarkers to help select the patients who can benefit most. We evaluate our investigational medicines in intelligently-designed, rigorously-conducted clinical trials to:

  • Assess their safety, tolerability and efficacy in patients
  • Understand how they work at the biological level and confirm their mechanism of action
  • Identify relevant biomarkers
  • Increase clinical development success by first establishing monotherapy activity, followed by potential combinations with other immuno-oncology and standard of care therapies

We believe in putting patients first. With that in mind, we report our preclinical and clinical data promptly and frequently at major scientific meetings, so our research can be used by others to advance medicine for the benefit of patients.

WHO WE ARE

We are committed to developing better medicines to improve the lives of people with cancer, immune disorders and infectious diseases

Join Our Team

Contribute your talent, expertise and desire to learn here at Corvus, where you can help improve the lives of people with cancer, immune disorders and infectious diseases